PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non–Small-Cell Lung Cancer

PURPOSE: PointBreak (A Study of Pemetrexed, Carboplatin and Bevacizumab in Patients With Nonsquamous Non-Small Cell Lung Cancer) compared the efficacy and safety of pemetrexed (Pem) plus carboplatin (C) plus bevacizumab (Bev) followed by pemetrexed plus bevacizumab (PemCBev) with paclitaxel (Pac) pl...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Oncol
Main Authors: Patel, Jyoti D., Socinski, Mark A., Garon, Edward B., Reynolds, Craig H., Spigel, David R., Olsen, Mark R., Hermann, Robert C., Jotte, Robert M., Beck, Thaddeus, Richards, Donald A., Guba, Susan C., Liu, Jingyi, Frimodt-Moller, Bente, John, William J., Obasaju, Coleman K., Pennella, Eduardo J., Bonomi, Philip, Govindan, Ramaswamy
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2013
Assuntos:
ORIGINAL REPORTS
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4881367/
https://ncbi.nlm.nih.gov/pubmed/24145346
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2012.47.9626
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados